Drug reference directory
Drug reference

Lactulose

Osmotic laxative / disaccharide / ammonia-lowering agent · Laxative; Ammonia detoxicant

Also known as Duphalac, Laevolac, Kristalose, Constilac

START
Constipation: 15 mL OD, titrate to 2-3 soft stools. HE: 30-45 mL TDS, titrate to 2-3 soft acidic stools (pH <6)
TYPICAL MAX
No fixed maximum; titrate to clinical endpoint; if >60 mL/day needed, consider adding rifaximin
STOP IF
Severe diarrhea, signs of dehydration, suspected bowel obstruction
WATCH
Stool frequency/consistency, mental status (HE), electrolytes (Na+, K+) with high doses
CDSCO approvedNon-scheduled or OTCJan AushadhiATC A06AD11
Dose laddermg/d
10start20titrate30titrate60ceiling
Renal dose adjustmenteGFR mL/min/1.73m²
FULLNo adjustment needed - not systemically absorbed0≥90

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours
1dONSET2dPEAK0st½1dDURATION
ONSET
1d · 24-48 hours for constipation; hours for HE
PEAK
2d · Peak osmotic effect
t½
0s · N/A - local colonic action
DURATION
1d · Daily dosing
EXCRETION
Fecal (unchanged and fermented)
route + CYP
INTERACTIONS
—
none in our sources
PREGNANCY
Safe in pregnancy; not systemically absorbed; widely used
FDA category + note
Available in India

258 branded formulations and 7 fixed-dose combinations. Look up specific brands in the Drugs workspace.

Jan Aushadhi — generic available at GoI pharmacies

Mechanism

Synthetic disaccharide (galactose + fructose) not absorbed in small intestine. Reaches colon intact where bacterial fermentation produces short-chain fatty acids (acetate, lactate) and lowers pH. Osmotic effect draws water into bowel lumen. In hepatic encephalopathy, acidification of colonic contents converts ammonia (NH3) to non-absorbable ammonium (NH4+), reducing systemic ammonia absorption.

Indications

Constipation (chronic and acute)Hepatic encephalopathy (prevention and treatment)Pre-operative bowel preparation (adjunct)Portal-systemic encephalopathy

Dosing

Adult
Constipation: 15-30 mL/day (10-20 g), titrate to 2-3 soft stools/day. HE: 30-45 mL TDS-QDS (30-60 g/day), titrate to 2-3 soft acidic stools/day
Pediatric
Constipation: <1 year: 2.5-5 mL/day; 1-6 years: 5-10 mL/day; 7-14 years: 10-15 mL/day. HE: limited pediatric data
Renal adjustment
No adjustment needed; not systemically absorbed
Hepatic adjustment
No adjustment needed; primary indication is hepatic encephalopathy
Geriatric
Start low (10 mL/day) and titrate; monitor electrolytes with long-term use
Max dose
No strict maximum; titrate to effect (2-3 soft stools/day)

Pharmacokinetics

Onset
Constipation: 24-48 hours; HE: hours to days
Peak effect
Variable; depends on colonic transit time and bacterial flora
Duration
Variable; dose-dependent
Half-life
N/A (not systemically absorbed)
Bioavailability
<1% (absorbed as metabolites only)
Protein binding
N/A
Metabolism
Colonic bacterial fermentation to SCFAs and gases
Excretion
Fecal (unchanged and fermented products)

Contraindications

  • Galactosemia
  • Intestinal obstruction
  • Hypersensitivity to lactulose
  • Low-galactose diet

Side effects

Common
FlatulenceAbdominal crampsBloatingNauseaDiarrhea (dose-related)Belching
Serious
  • Severe diarrhea leading to dehydration and electrolyte imbalance
  • Hypernatremia (with high doses in HE)
  • Bowel perforation (if obstruction present)

Pregnancy & lactation

Pregnancy

Safe in pregnancy; not systemically absorbed; widely used

Lactation

Minimal systemic absorption; compatible with breastfeeding

Drug interactions

12 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.

Related guidelines

Ask House about Lactulose

Continue into a citation-backed clinical answer with the drug context already attached.

Textbook-sourced·Sources: Goodman & Gilman 14e, Katzung, BNF, Nelson·Updated: 2026-05-19·Cockpit curated: 2026-05-19